TriNetX expands network: Pharma to ‘spin-up sites and recruit patients faster’

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/m1366)
(Image: iStock/m1366)

Related tags: Clinical trial, Medicine, Pharmaceutical industry

Weill Cornell Medicine has joined TriNetX’s global health research network, enabling it to collaborate with researchers and attract clinical trial opportunities.

Weill Cornell Medicine is an integrated academic healthcare delivery system, and as a TriNetX global health research network member, its patient population data is now available for query through TriNetX’s federated network.

The de-identified data includes patient demographics, diagnoses, procedures, labs, and medications, for a total population of more than two million.

Gadi Lachman, CEO of TriNetX, told us that as a network member, Weill Cornell has the ability to collaborate with researchers at more than 68 healthcare organizations. It will also be able to attract clinical trial opportunities from pharmaceutical companies and contract research organizations (CROs).  

With the addition of every new healthcare organization to the TriNetX network, comes the opportunity for pharmaceutical companies to operationalize clinical trials in that community, enabling the healthcare provider to present new therapies to its patients and allowing pharmaceutical companies to spin-up sites and recruit patients faster​,” said Lachman.

The TriNetX network includes healthcare organizations representing approximately 100m patients globally, as well as biopharmaceutical companies and CROs. Members are able to use the company’s cloud-based health research platform to analyze patient populations and perform “what-if​” analyses in real-time.

Additionally, Lachman said a huge benefit for TriNetX’s healthcare organizations is peer-to-peer collaboration. “TriNetX handles the mapping and curating of data so that hospitals do not have to expend IT resources normalizing their data to an external standard in order to support multi-site research​,” he explained.

Collaborations and growth

Earlier this month, TriNetX announced a partnership with Sanofi​, through which it will work to reduce clinical trial complexity and speed development timelines for the pharma company.

The goal of the partnership is “to simplify and to make better, earlier, and more informed decisions​,” said Vicky DiBiaso, global head of clinical operations strategy and collaboration within Sanofi’s R&D organization.

Late last year, TriNetX also completed a yearlong project to move its headquarters​ to Cambridge, MA.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars